Oncolytics Biotech Inc.
ONCY
$0.80
-$0.01-1.24%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -63.11% | -45.08% | -23.53% | -31.77% | -12.52% |
| Total Depreciation and Amortization | -50.78% | -227.14% | -132.53% | -111.02% | -108.05% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 294.26% | 625.84% | 2,837.39% | 315.56% | 195.56% |
| Change in Net Operating Assets | -133.43% | -82.54% | -71.20% | -97.74% | -65.32% |
| Cash from Operations | -41.19% | -14.64% | 2.23% | -9.13% | 2.79% |
| Capital Expenditure | 67.21% | 91.99% | 96.17% | 89.49% | 75.53% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 67.21% | 91.99% | 96.17% | 89.49% | -100.75% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 32.25% | 345.99% | 261.64% | 120.28% | 124.71% |
| Issuance of Common Stock | 98.97% | 109.77% | 142.24% | 260.30% | -61.22% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -298.78% | 39.44% | 72.56% | -90.19% | -76.67% |
| Cash from Financing | 86.25% | 113.69% | 174.49% | 278.27% | -44.75% |
| Foreign Exchange rate Adjustments | 170.00% | 194.53% | 401.88% | -999.79% | -243.02% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 32.50% | 63.46% | 66.95% | 55.41% | -258.39% |